This statistic depicts the percentage of select orphan drugs' 2017 revenues in the U.S. by orphan or non-orphan use. According to the source, 88.7 percent of nivolumab (Opidivo) sales were for non-orphan uses.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA. (October 24, 2018). Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017 [Graph]. In Statista. Retrieved June 07, 2025, from https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/
IQVIA. "Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017." Chart. October 24, 2018. Statista. Accessed June 07, 2025. https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/
IQVIA. (2018). Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017. Statista. Statista Inc.. Accessed: June 07, 2025. https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/
IQVIA. "Percentage of Select Orphan Drugs' U.S. Revenues Attributable to Non-orphan Usage in 2017." Statista, Statista Inc., 24 Oct 2018, https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/
IQVIA, Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017 Statista, https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/ (last visited June 07, 2025)
Percentage of select orphan drugs' U.S. revenues attributable to non-orphan usage in 2017 [Graph], IQVIA, October 24, 2018. [Online]. Available: https://www.statista.com/statistics/979256/select-orphan-drug-us-sales-by-non-orphan-use/
